Illumina (NASDAQ:ILMN) Updates FY25 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY25 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $4.50 for the period, compared to the consensus estimate of $4.51.

Illumina Trading Down 0.8 %

Shares of NASDAQ ILMN traded down $0.65 during mid-day trading on Monday, hitting $85.97. The stock had a trading volume of 2,960,847 shares, compared to its average volume of 2,655,172. The business has a 50 day moving average price of $118.38 and a two-hundred day moving average price of $131.48. Illumina has a 1 year low of $80.18 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a market cap of $13.62 billion, a P/E ratio of -11.19, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts anticipate that Illumina will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent analyst reports. Morgan Stanley decreased their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Citigroup decreased their price objective on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Stephens lifted their target price on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Robert W. Baird decreased their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Finally, TD Cowen cut Illumina from a “buy” rating to a “hold” rating and cut their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $149.25.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.